Astrocytes are increasingly being recognized as dynamic participants in many aspects of normal central nervous system function. In disease states, reactive astrocytes undergo complex phenotypic changes, generically referred to as astrogliosis. Unraveling the functions of reactive astrocytes and underlying molecular mechanisms is a difficult problem. The use of genetically modified mice is beginning to yield some answers to long-standing questions in the field. What are the functions of reactive astrocytes? What extracellular factors and intracellular signaling mechanisms are responsible for astrocyte activation in various forms of neural injury? In this review we will highlight studies using astrocyte reporter lines for cellular imaging and lineage tracing, as well as gain-and loss-of-function mutations that have begun to shed light on mechanisms of astrogliosis.
INTRODUCTION
Astrocytes, also known as astroglia, are the most numerous cell type in the CNS. Since the cells were first named by Michael von Lenhossek in 1893 (see the introductory chapter to Ref. 1 for an interesting historical discussion), they have accrued an impressive resume of proposed functions. These include structural support of the fragile neuronal network, regulation of ionic homeostasis in the extracellular space, regulation of energy metabolism and coupling of neuronal activity to blood flow, induction and maintenance of the blood-brain barrier, and, remarkably, service as bona fide stem cells in the adult CNS (1Y3). The diversity of astrocyte functions combined with our current primitive classification system (Bfibrous[ vs Bprotoplasmic[) has been a barrier to progress in the field. A provocative discussion of the issue of astrocyte identity was recently published (4) . The discovery that astrocytes not only take up and release neurotransmitters but also are highly communicative participants at the synapse has led to the concept of the Btripartite synapse[ (5).
Consideration of roles for astrocytes in the diseased CNS must take into account loss or diminishment of these myriad functions, as well as acquisition of potentially novel roles in disease states, both beneficial and detrimental. The response of astrocytes to injury, variably referred to as astrocytosis or astrogliosis, is a ubiquitous response to CNS damage by trauma, ischemia, degeneration, or infection. Several excellent general reviews on reactive astrogliosis have recently been published (6Y8). The ubiquity of this response and the almost exclusive use of glial fibrillary acidic protein (GFAP) immunohistochemistry for its study have limited our ability to advance knowledge of specific molecular mechanisms underlying what are surely many different kinds of astroglial reactions. The relative intractability of the problem was asked of one of us by a leading glial cell biologist: Bwhy study reactive astrocytes when we have only just begun to understand functions of normal astrocytes?[ Although we still ask ourselves this very valid question, we will argue that the growing base of knowledge about astrocytes and the tools afforded by mouse genetics allow meaningful investigations of astrogliosis.
In this review we will focus on mouse models that provide some insight into the functions of reactive astrocytes and the molecular mechanisms underlying astrogliosis. Three general approaches will be discussed: 1) reporter mice for imaging astroglia in situ; 2) gain-of-function mutants to test the sufficiency of activation of a particular gene/protein for astroglial activation; and 3) loss-of-function mutants to test necessity.
You Can Observe a Lot Just by Watching: Genetic Approaches Allow In Vivo Visualization of Astrocytes
The first genetic reporter mouse for astrocytes used a transgene combining 2 kb of the murine GFAP promoter with the A-galactosidase gene, allowing histochemical visualization of astrocytes (9) . The jellyfish green fluorescent protein (GFP) revolutionized cell and tissue imaging studies because of its native fluorescence, allowing live imaging. The first GFAP-GFP transgenic mice expressed the humanized GFP variant (hGFP-S65T) under the control of 2 kb of the human GFAP promoter (10) . GFP-expressing astrocytes were observed throughout the CNS, and neurons were unlabeled. Subsequent improvements included Copyright @ 2007 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited. expression of enhanced GFP (EGFP) as well as several varieties of fluorescent coral proteins (11Y13). An advantage of labeling cells by expression of EGFP is that, unlike with GFAP immunostaining, the entire cytoplasmic volume is visualized, similar to classical Golgi impregnation staining methods. As expected, after cortical injury these mice showed an increased in the number and/or brightness of EGFP-expressing astrocytes lining the stab wound (11) . The real power of the fluorescent protein reporter mice is the ability to image living astrocytes in situ. Shape changes of astrocytes in response to hypotonic stress were characterized by confocal microscopic three-dimensional-reconstruction methods in cortical slices of GFAP-EGFP mice (14) . Visualization of fluorescent protein-expressing astrocytes in acute brain slice preparations allowed observation of novel modes of process motility at synaptic contacts (15) . Recent work has revealed dramatic injury-induced microglial process motility, but apparently little astrocyte process motility (16) . Further work is needed to determine whether other forms of injury or agents can promote motility of astrocyte processes or cell migration.
For the case of GFAP-expressing progenitors (radial glia or astrocytes), fate-mapping experiments were made possible by crossing GFAP-Cre mice with a Cre reporter strain (17) . Cre recombinase, expressed only in GFAPpositive cells, excises a stop cassette flanked by loxP sites, thus permanently turning on either A-galactosidase or EGFP expression in that cell and all of its progeny. The choice of specific GFAP promoters (human versus mouse) appears to influence the results of this type of experiment, the details of which are beyond the scope of this review. Interestingly, it was shown that the widely used Cre reporter strains Rosa26R and Z/AP were poor reporters of recombination in astrocytes, leading the authors to generate a new astrocyte-specific Cre reporter, ACR, in which EGFP is expressed under the control of the human GFAP promoter (18) . Examples of astrocyte imaging in ACR mice are shown in Figure 1A , B (JW Mandell, DS Heffron, KB Casper, and KD McCarthy, unpublished data, 2006) . The general concept of fate mapping could be applied to examine alterations in the extent and pattern of neurogenesis and gliogenesis in injury and disease states. Clonal analysis, a specialized form of fate mapping, requires labeling of single or very sparse cells to visualize the progeny of a single cell. Traditionally this was done using dye or viral injection methods into embryos. Recently, development of a mouse expressing an inducible form of Cre recombinase fused to the ligand-binding domain of the estrogen receptor (Cre-ERT2) has allowed a noninvasive strategy for clonal analysis in the brain (19) . By using low doses of tamoxifen, very low levels of Cre-mediated recombination allow sparse cell marking. This approach could provide a means to perform clonal analysis in disease and injury models to determine the fate of cells produced by reactive astroglia.
Noninvasive Imaging of Astrogliosis With Luciferase
The ability to image and measure astrogliosis noninvasively would open many new areas of investigation.
Two lines of luciferase-expressing mice that have utility in monitoring astrogliosis have been described. Mice expressing luciferase under the control of the GFAP promoter were used to demonstrate proof of concept (20) . Subsequently, this reporter strain was used to monitor the brain response to pneumococcal meningitis (21) . By using a Streptococcus pneumoniae strain expressing a luciferase with different spectral properties and substrate preference, it was possible to simultaneously image the pathogen and the astroglial response in real time. To image signaling activity via the transforming growth factor (TGF)-A receptor, a Smad reporter mouse that expresses luciferase under the control of a promoter containing Smad-responsive elements was used (22) . Kainateinduced neurodegeneration caused an early signal increase at 24 hours, attributed to neuronal activation, and a delayed signal increase at 3 to 5 days, due to microglial and astroglial activation. Although not an astrocyte-specific reporter, future refinements might include generation of a dual-luciferase transgenic mouse allowing imaging of both a specific signaling event and an astrocyte-specific marker.
Turn It On: Gain-of-Function Mutants Infantile Gliosis, A Spontaneous Mutant
A mutant strain exhibiting early neonatal onset of astrogliosis and neuropil vacuolization was discovered at the Jackson laboratory in 1992 and recently has been further characterized (http://www.jax.org/mmr/gliosis_paper.html). The mutation is linked to chromosome 8, but the responsible gene has not yet been identified.
c-mos
Transgenic mice overexpressing the c-mos protooncogene under the control of retroviral transcriptional control elements were found to exhibit striking astrogliosis, but this was attributed to a secondary response to neurodegeneration (23) . We have re-examined brains from several lines of these mice (provided by Dr. G. F. Vande Woude). In many cases, the degree and atypicality of the astrogliosis appears to be out of proportion to the level of neuronal degeneration (Fig. 1C) . Thus, it is possible that c-mos, a direct and potent activator of mitogen-activated protein kinase kinase 1/2 and the downstream mitogen-activated protein kinase cascade, stimulates aspects of astrogliosis in a cell-autonomous manner. This is consistent with our observations of chronically activated (phosphorylated) extracellular signal-regulated kinase (ERK)/mitogen-activated protein (MAP) kinase in human and murine reactive astrocytes (24, 25) . Direct testing of this hypothesis will require generation of an astrocyte-specific transgenic c-mos mouse.
Transforming Growth Factor->
The epidermal growth factor receptor (EGFR) and its associated ligands have long been implicated in astrogliosis. To test this notion, an inducible transgenic mouse was studied in which human TGF-> is expressed under the control of a zinc-inducible mouse metallothionein 1 (MT1) promoter (26) . Induction of expression was achieved by providing ZnCl 2 in the drinking water for 3 weeks. Induced mice exhibited hippocampal astrogliosis compared with the uninduced controls. The reactive astrocytes exhibited hypertrophy, increased GFAP immunoreactivity, and increased levels of phosphorylated EGFR, consistent with a direct action of overexpressed TGF-> on the EGFR. The mice did not show any signs of microglial activation, leading the authors to suggest a potential divergence in the signals that regulate astroglial and microglial reactivity. This is an important observation, because several lines of investigation suggested that astrogliosis is largely secondary to microglial activation and interleukin secretion (27) .
Interleukin-6
GFAP-interleukin (IL)-6 mice were the first astrocytetargeted transgenic line shown to exhibit spontaneous astrogliosis, in conjunction with severe neurologic phenotypes including seizures and ataxia (28) . Later work with these mice revealed an enhanced astroglial response, as visualized by elevated and prolonged GFAP expression, as well as more rapid wound closure in a cryolesion model (29) . Moreover, neuronal apoptosis was markedly decreased in the IL-6 overexpressors. This seeming paradox, that an animal with spontaneous astrogliosis and neurologic disease should fare better than a normal animal after traumatic brain injury, deserves scrutiny. The authors proposed that the functional outcome of IL-6 expression, known to have both proinflammatory and neuroprotective roles, may depend on context. In the normal brain, IL-6 is primarily proinflammatory, leading to microglial and astroglial activation and neuronal dysfunction. In acute brain trauma, however, it can induce expression of factors with antioxidant and antiapoptotic properties, leading to a favorable outcome.
SOD1
Many investigations of amyotrophic lateral sclerosis (ALS), both in human tissues and mouse models, indicate that the degree of astrogliosis is out of proportion to the extent of motor neuron loss, suggesting that astrocytes could be primarily affected by the disease (30) . Experimental evidence that the familial ALS G93A-SOD1 mutation induces a cell-autonomous reactive phenotype in astrocytes was shown both in vivo and in vitro. Expressing a mutant SOD1 in astrocytes by use of the GFAP promoter was shown to lead to astrocyte hypertrophy and GFAP elevation but no sign of motor neuron degeneration (31) . As discussed previously, the use of the GFAP promoter in transgenic models has the issue of expression in GFAP-positive radial glia and other precursor/stem cells during development, so this study cannot be considered proof of cell-autonomous astrogliosis caused by the mutant SOD1. The in vitro studies, on the other hand, showed unambiguous evidence of a primary effect on astroglia. Astrocytes cultured from G93A-SOD1 mice before any signs of neurodegeneration had significant elevations in basal and tumor necrosis factor >-stimulated levels of proinflammatory eicosanoids prostaglandin E 2 and leukotriene B 4 as well as elevated inducible nitric oxide synthase (32) . It seems likely that other neurodegenerative diseases could result from or be exacerbated by primary astroglial defects.
Turn it Off: Loss-of-Function Mutants Pharmacologic/Genetic Astrocyte Ablation Models
At the cellular level, a reactive astrocyte loss-offunction model would allow direct tests of function. A combined pharmacologic/genetic approach to ablate reactive astrocytes was taken by creating a transgenic mouse expressing the herpes simplex virus enzyme thymidine kinase under the control of the murine GFAP promoter (33) . Upon administration of ganciclovir, dividing reactive astrocytes expressing thymidine kinase generate a toxic product and rapidly die. Using this ablation strategy, several aspects of the response to cortical stab injury were studied. Perilesional brain parenchyma depleted of GFAP-positive astrocytes showed a remarkable increase in the intensity of leukocyte infiltration and a local increase in axonal regeneration, but delayed repair of the blood-brain barrier. These findings supported the long-held notion that reactive astrocytes acted as a barrier to axonal regeneration but also highlighted an unexpected role in monitoring of leukocyte trafficking into injured brain. In the hippocampus, loss of reactive astrocytes was associated with increased hippocampal neuronal death, which could be rescued by a glutamate receptor antagonist, suggesting a role for reactive astrocytes in protection from excitotoxicity. One limitation of this approach is that it only ablates dividing reactive astrocytes, which are outnumbered by nondividing reactive astrocytes in most pathologic conditions. Other selective toxin expression systems may allow methods to target the larger population of nondividing reactive astrocytes.
Traditional knockout mice are created by gene targeting with homologous recombination in embryonic stem cells, followed by injection into blastocysts (Fig. 2C) . It is estimated that approximately 2,500 genes, or approximately 10% of known genes, have been targeted for knockout models (34) . Only a handful of these mutants have been carefully examined for CNS phenotypes and even fewer have been directly studied for phenotypes related to astrogliosis. Some of the more informative knockouts are discussed below.
Glial Fibrillary Acidic Protein and Vimentin
Given their widespread use as markers of reactive astrocytes, it is not surprising that knockouts of the intermediate filament proteins GFAP and vimentin were studied by several laboratories. Several independent studies characterized both single and double knockouts of these two intermediate filaments (6, 35) . Single knockouts of either GFAP or vimentin showed no major CNS phenotypes. However, double knockout (GFAP j/j ; VIM j/j ) mice failed to form any intermediate filaments in normal or reactive states and were shown to have interesting CNS phenotypes. After spinal cord injury, double knockout mice showed looser and less organized glial scars. By using the entorhinal cortex lesion model, it was found that double knockout mice initially lost a larger number of synapses than wild-type mice, but by 10 days showed markedly greater rates of synaptogenesis. How an alteration of the intermediate filament cytoskeleton in astrocytes can influence synaptic remodeling and synaptogenesis is an area worthy of further investigation.
Clusterin
Clusterin is an extracellular glycoprotein (also known as apolipoprotein J) known to be upregulated in many cell types in disease and injury states. Clusterin expression was noted to increase in reactive astrocytes surrounding an ischemic lesion. A role for clusterin in astrocyte function in ischemic brain injury was suggested by the observation that clusterin j/j mice showed significantly elevated GFAP expression within reactive astrocytes as well as increased peri-infarct volume (36) .
Smad3
TGF-A is strongly implicated as a key factor in many tissue injury responses, including those of the CNS. Because TGF-A signaling involves activation of the transcription factor Smad3, the CNS injury response of Smad3-null mice was recently examined (37) . Knockout animals showed fewer neutrophils, macrophages/microglia, NG2-positive cells, and GFAP-positive cells immediately around the lesion. Deposition of fibronectin and laminin was also reduced. Whether these altered responses are due to diminished TGF-Smad3 signaling in astrocytes or in other CNS cell types will need to be addressed using astrocytespecific conditional knockout approaches.
Fibroblast Growth Factor 2
The fibroblast growth factors (FGFs), especially FGF2 (basic FGF), have been strongly implicated in the transition of astrocytes from quiescent to reactive. Examination of FGF2 knockout mice revealed a baseline decrease in GFAP immunoreactivity in cortex and striatum (38) . Animals deficient in both FGF2 and FGF5 were also found to have altered perivascular endfoot structure and associated bloodbrain barrier abnormalities. Whether these and other FGFs are important for triggering and/or maintenance of astrogliosis remains to be determined.
Interleukin-1A and Interleukin-1 Receptor
IL-1 is a well-studied activator of immune cell responses. In CNS injury, many lines of investigation suggest that early microglial/macrophage production of IL-1 leads to astrogliosis. A direct test of this hypothesis was achieved by analyzing the response of brain tissue to focal injury in IL-1A knockout mice (39) . The early upregulation of GFAP mRNA and protein seen in wild-type mice was absent in the knockout mice. Moreover, knockout mice exhibited defective repair of the blood-brain barrier, indicating an important protective role for IL-1A-induced astrogliosis. It should be noted, however, that the delayed (5Y7 days) upregulation of GFAP was unaffected in the knockout mice, indicating the multiplicity of signals involved in astrogliosis.
Another test of the importance of IL-1 in astrogliosis came from studies on IL-1 receptor-null mice. Whereas GFAP upregulation was delayed after focal injury, induction of chondroitin sulfate proteoglycans, tenascin, and S-100B as well as glutamate transporter proteins, GLAST and GLT-1, and glutamine synthetase were not affected (40) . Thus, many hallmarks of the astroglial scar were regulated independently of IL-1 receptor activation, again emphasizing the plurality of signals involved in this complex cellular reaction. injured tissue and compacted the inflammatory cell population. In a neural-specific conditional knockout of Stat3 (created by crossing nestin-Cre mice with those harboring a floxed Stat3 allele), this migratory and compaction was greatly delayed and diminished (41) . Conversely, in mice with conditional knockout of Socs3 (a suppressor of cytokine-induced signaling through Stat3), the migratory response and compaction were enhanced compared with wild-type control mice. The Socs3 knockout mice also fared better in motor testing than control mice after a spinal cord lesion. This work provides compelling evidence for a beneficial role for Stat3-mediated induction of glial reactions. Whether the phenotype was due to loss of Stat3 function in astrocytes, NG2-positive glia, oligodendrocytes, or neurons, cannot be definitively determined since the nestin-Cre recombination is pan-neural.
Nf1
The study of neurofibromatosis has provided important insights into mechanisms of astrogliosis. Before the causative gene (NF1) mutation was identified, careful neuropathologic studies revealed a variety of morphologic forms of astrogliosis in autopsy studies of patients with central forms of neurofibromatosis (42, 43) . Identification of the tumor suppressor gene NF1 as the target of mutation in this disease was followed by creation of mouse Nf1 knockout models. In addition to predisposition to some of the neoplasms associated with the disease, affected mice were also shown to exhibit spontaneous astrogliosis (44) . Brains from affected mice showed elevated Ras activation, consistent with the known function of Nf1 as a negative regulator of Ras. Evidence that the observed astrogliosis was cell-autonomous and not secondary to neurodegeneration came from similar observations in conditional knockouts of NF1 made by crossing a GFAP-Cre mouse with mice harboring a floxed NF1 allele (45) . Some aspects of the reactive astrogliosis seen in this study were probably secondary to neuronal dysfunction, however, as a prior study using a synapsin-Cre mouse (neuron-specific) found astrogliosis without evidence of astrocyte recombination (46) . Other aspects of astrogliosis, such as ERK/MAP kinase activation and expression of nestin, however, were only seen in the GFAP-Cre cross, suggesting that these features were indeed cell autonomous.
Abr and Bcr, Negative Regulators of Rac
Like Ras, Rac is a small GTPase signaling protein with diverse functional roles. Simultaneous disruption of two negative regulators of Rac, Abr and Bcr, in mice leads to defects in cerebellar development related to functional and structural abnormalities of glial cells (47) . Spontaneous astrogliosis was observed in midbrain structures and the double knockout animals showed an enhanced astrogliotic response to kainate lesion. Thus, unrestrained Rac activation, like Ras, may underlie some forms of astrogliosis.
The Cutting Edge: Astrocyte-Specific, Temporally Controlled Gene Expression/ Recombination Astrocyte-Specific Tetracycline-Regulated Transgenics
Tetracycline-regulatable gene expression systems have been in use for over a decade (48, 49) . These systems require two components: a tetracycline-responsive regulator (tTA) created by fusing an Escherichia coli tet repressor to the transactivation domain of herpes simplex virus VP16 protein under a generic (cytomegalovirus) promoter, and a tTAdependent, RNA polymerase II promoter-driven expression (Tet-responsive element) for the gene of interest (Fig. 2B) .
Two variants of the system have been developed: a Tet-off system in which addition of tetracycline prevents transcription by binding to tTA and the gene of interest is expressed only after withdrawal of tetracycline, and the Teton system that uses a reverse tTA element (rtTA) that requires addition of tetracycline or doxycycline for expression. Successful implementation of a Tet-on, GFAP promoter-regulated transgene was reported in a study of the in vivo neuropathologic effects of the human immunodeficiency virus (HIV) Tat protein (50) . This approach was crucial to the study because conventional Tat transgenic models showed significant developmental consequences, precluding a valid model of adult HIV encephalopathy. By delaying induction of Tat to adulthood, the authors were able to show that Tat expression in astrocytes is sufficient to induce astrogliosis, edema, dendritic degeneration, neuronal apoptosis, and inflammatory infiltrates. Application of the astrocyte-specific Tet-on system should provide many informative tests of gene function in astrogliosis. A potential pitfall in using tetracycline/doxycycline-regulatable systems is that this family of antibiotic compounds is known to have anti-inflammatory properties, diminishing microglial responses in brain ischemia (51) . In addition, long-term treatment of mice with these compounds has effects on memory formation (52) . For these reasons, rigorous controls are necessary to separate tetracycline/doxycycline effects from those of induced or ablated gene expression.
Astrocyte-Specific Cre/lox-Mediated Recombination GFAP-CreERT2 and GLAST-CreERT2 Mice Cre/lox-mediated recombination allows permanent genetic alteration of GFAP-expressing cells (Fig. 2D ). An advance in this technology was the creation of an inducible form of Cre, CreERT2, created by fusion with the mutated ligand-binding domain of the human estrogen receptor. This fusion protein does not bind endogenous estradiol but is highly sensitive to nanomolar concentrations of administered tamoxifen. Transgenic lines expressing CreERT2 under the control of the GFAP promoter were recently characterized by crossing to Cre reporter lines expressing autofluorescent proteins (53) . Similarly, other lines expressing CreERT2 under the control of the astrocyte-specific glutamate transporter GLAST were successfully characterized (54) . To date, neither of these lines has been reported in experiments to delete floxed genes of interest. They should prove to be powerful tools to study astrogliosis, allowing precisely timed control of astroglial-selective gene recombination in the adult CNS.
CONCLUSIONS
Because many aspects of astrogliosis cannot be realistically modeled in a culture dish, clever in vivo approaches are necessary. The use of genetically modified mice is beginning to shed light on previously unapproachable questions about this important cellular reaction. Use of autofluorescent reporter mice can reveal information about the dynamic and motile properties of astrocytes in injury and disease states. Fate mapping and lineage tracing experiments using Cre/lox strategies will reveal the contribution of regional astrocyte subpopulations to neurogenesis and gliogenesis in disease states. Real-time, noninvasive imaging of astrogliosis is now possible using luciferase-expressing mice. Although this technology only provides coarse anatomical localization of reporter activity, further refinements will bring the method closer to cellular resolution. Finally, testing of specific molecular mechanisms underlying astrocyte activation is now approachable using astrocytespecific, inducible transgenic and knockout models.
